Holen Sie sich die Stockscreener-App
15.55
1.57%
0.22
Schlusskurs vom Vortag:
$15.33
Offen:
$15.06
24-Stunden-Volumen:
245.07K
Relative Volume:
1.02
Marktkapitalisierung:
$236.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-60.28%
1M Leistung:
-70.43%
6M Leistung:
-52.12%
1J Leistung:
+0.00%
1-Tages-Spanne:
$14.44
$16.15
1-Wochen-Bereich:
$14.44
$39.20
52-Wochen-Spanne:
$14.44
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NGNE | 15.62 | 236.66M | 0 | 0 | 0 | 0.00 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.61 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.08 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
FY2024 EPS Estimates for Neurogene Lowered by William Blair - MarketBeat
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene price target lowered to $45 from $60 at BMO Capital - TipRanks
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week - MSN
Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles - TipRanks
Neurogene (NASDAQ:NGNE) Earns Outperform Rating from William Blair - MarketBeat
Neurogene’s Value Tanks On Gene Therapy Side-Effect Details - Citeline News & Insights
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect - AccessWire
Neurogene (NASDAQ:NGNE) Receives "Buy" Rating from HC Wainwright - MarketBeat
Neurogene: Q3 Earnings Snapshot - CT Insider
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene Inc reports results for the quarter ended September 30Earnings Summary - XM
Neurogene Inc (NGNE) Quarterly 10-Q Report - Quartzy
Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neurogene Reports Promising Rett Syndrome Trial Data Despite Wider Q3 Loss | NGNE Stock News - StockTitan
Stock Market News: QMMM Holdings plunges by 69% whereas Neurogene falls by 44.05% during mid day trading - Business Upturn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect - AccessWire
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Neurogene stock plunges 36% on NGN-401 study update (NASDAQ:NGNE) - Seeking Alpha
Neurogene falls again on Rett gene therapy side effects - pharmaphorum
NGNENeurogene, Inc. Latest Stock News & Market Updates - StockTitan
Neurogene Drops High-Dose Cohort of Gene-Therapy Study for Rett Syndrome - MarketWatch
Neurogene Adjusts NGN-401 Trial After Adverse Event - TipRanks
Neurogene Halts High-Dose Rett Syndrome Trial After Critical Safety Event, FDA Clears Low Dose | NGNE Stock News - StockTitan
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Neurogene To Report Rett Syndrome Trial Data Next WeekStock Up 90% In 8 Months - RTTNews
Janus Henderson Group PLC's Strategic Reduction in Neurogene Inc Holdings - GuruFocus.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - AccessWire
RTW INVESTMENTS, LP Expands Stake in Neurogene Inc - GuruFocus.com
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" - sharewise
Acadia Healthcr Company (ACHC-Q) QuotePress Release - The Globe and Mail
Neurogene (NASDAQ:NGNE) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out - AccessWire
Neurogene’s NGN-401 gene therapy scores well in Rett syndrome - The Pharma Letter
Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect - MSN
FMR LLC Expands Stake in Neurogene Inc - GuruFocus.com
Neurogene shares target lifted, outperform on positive data By Investing.com - Investing.com Canada
Neurogene stock target up as Stifel notes consistent efficacy despite emerging safety concerns - Investing.com Canada
Neurogene’s Rett Data Draw Optimism Despite Serious Adverse Event - Citeline News & Insights
Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors - MedCity News
Neurogene stock target cut, reiterates outperform on trial results By Investing.com - Investing.com Canada
U.S. Stock market top losers: Neurogene Inc. declines by 46.04% while Pagaya Technologies falls by 34.87% during mid day trading - Business Upturn
U.S. Stock market: BTC Digital(+314.68%), BTCS Inc.(+35.64%), Neuronetics(−41.36%) among most volatile stocks during mid day trading - Business Upturn
Neurogene shares target lifted, outperform on positive data - Investing.com
Neurogene shares fall on Rett syndrome gene therapy data - pharmaphorum
Neurogene hits a setback in the clinic, days after fundraise - BioPharma Dive
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial - Benzinga
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):